Special Issue

Protein Degradation-Based Drug Discovery (PDBDD) Approach: Proteolysis Targeting Chimeras (PROTACs)

Message from the Guest Editor

Protein degradation-based drug discovery (PDBDD) via proteolysis targeting chimeras (PROTACs) represents a paradigm-shifting approach in small molecule drug discovery and development toward novel medications for some severe human diseases, particularly anticancer agents. Despite the fact that development of protein degraders is still at an early stage, PROTACs and related molecules capable of selectively inducing targeted protein degradation by the ubiquitin–proteasome system offer one of the most appealing therapeutic strategies with potential advantages over traditional occupancy-based inhibitors in various aspects, such as superior target specificity, better efficacy at lower dose, fewer side effects, overcoming drug resistance and modulating “undruggable” drug targets. I would like to thank all the authors for their tremendous effort, dedication, and excellent contribution to this Special Issue. I hope that this issue will serve as a key reference work for medicinal chemists, chemical biologists, pharmacologists, and other research investigators engaged or interested in protein degradation and target-based drug discovery and development.

Guest Editor

Prof. Dr. Jia Zhou

Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, USA

Deadline for manuscript submissions

closed (30 September 2022)

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/si/85078

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

mdpi.com/journal/molecules

Molecules

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed

mdpi.com/journal/molecules

MDPI

About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt
Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).